Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Frontiers in Medicine

• Publication date

  2015-03-02

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s11684-015-0375-1PMID 25511620
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.

  2014cited by this paper
• Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO

  2014cited by this paper
• Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)

  2013cited by this paper
• Oxidative stress in sickle cell disease

  2013cited by this paper
• A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes

  2013cited by this paper
• Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders

  2013cited by this paper
• Oxidative stress in sickle cell disease: an overview of erythrocyte redox metabolism and current antioxidant therapeutic strategies.

  2013influential reference
• Fetal hemoglobin in sickle cell anemia: a glass half full?

  2013cited by this paper
• Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

  2013cited by this paper
• The switch from fetal to adult hemoglobin.

  2013cited by this paper
• N-acetylcysteine reduces oxidative stress in sickle cell patients

  2012cited by this paper
• Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease

  2012influential reference
• Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine.

  2012influential reference
• The influence of hydroxyurea on oxidative stress in sickle cell anemia

  2012cited by this paper
• Assessment of oxidative stress in patients with sickle cell disease: The glutathione system and the oxidant-antioxidant status.

  2011cited by this paper
• Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

  2011cited by this paper
• Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial.

  2011cited by this paper
• Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia.

  2011cited by this paper
• New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress

  2011influential reference
• Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management

  2011influential reference
• Targeting iNKT cells for the treatment of sickle cell disease.

  2011cited by this paper
• Sickle-cell disease

  2010cited by this paper
• microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease.

  2010influential reference
• Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease

  2009cited by this paper
• Active NF-E2-related Factor (Nrf2) Contributes to Keep Endothelial NO Synthase (eNOS) in the Coupled State

  2009cited by this paper
• Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice.

  2009cited by this paper
• Mechanisms of vasculopathy in sickle cell disease and thalassemia.

  2008influential reference
• Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.

  2008influential reference
• Red blood cells induce hypoxic lung inflammation.

  2008cited by this paper
• Oxidative process in erythrocytes of individuals with hemoglobin S

  2008cited by this paper
• Nrf2 as a Master Redox Switch in Turning on the Cellular Signaling Involved in the Induction of Cytoprotective Genes by Some Chemopreventive Phytochemicals

  2008cited by this paper
• Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease.

  2008cited by this paper
• Blood antioxidant parameters in sickle cell anemia patients in steady state.

  2008cited by this paper
• Energy Expenditure, Inflammation, and Oxidative Stress in Steady-State Adolescents With Sickle Cell Anemia

  2007cited by this paper
• SICKLE CELL DISEASE: ROLE OF REACTIVE OXYGEN AND NITROGEN METABOLITES

  2007influential reference
• Asthma is associated with increased mortality in individuals with sickle cell anemia.

  2007cited by this paper
• Preclinical Evaluation of Targeting the Nrf2 Pathway by Triterpenoids (CDDO-Im and CDDO-Me) for Protection from LPS-Induced Inflammatory Response and Reactive Oxygen Species in Human Peripheral Blood Mononuclear Cells and Neutrophils

  2007cited by this paper
• Chemopreventive promise of targeting the Nrf2 pathway.

  2007cited by this paper
• Induction of fetal hemoglobin in the treatment of sickle cell disease.

  2006cited by this paper
• Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide.

  2006cited by this paper
• Pathophysiologically based drug treatment of sickle cell disease.

  2006influential reference
• Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

  2006cited by this paper
• Understanding mechanisms of γ‐globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction

  2006cited by this paper
• Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction.

  2006cited by this paper
• Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress.

  2005cited by this paper
• Role of Nrf2 signaling in regulation of antioxidants and phase 2 enzymes in cardiac fibroblasts: Protection against reactive oxygen and nitrogen species‐induced cell injury

  2005cited by this paper
• Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease

  2005cited by this paper
• The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.

  2005cited by this paper
• Nrf2, a multi‐organ protector?

  2005cited by this paper
• Nitric oxide production from hydroxyurea.

  2004cited by this paper
• Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

  2004cited by this paper
• The transcription factor NRF2 protects against pulmonary fibrosis

  2004cited by this paper
• Aging and oxidative stress.

  2004cited by this paper
• Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

  2003cited by this paper
• Effects of N‐acetylcysteine on dense cell formation in sickle cell disease

  2003cited by this paper
• Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.

  2003cited by this paper
• Keap1 regulates both cytoplasmic‐nuclear shuttling and degradation of Nrf2 in response to electrophiles

  2003cited by this paper
• Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease

  2002cited by this paper
• Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

  2002cited by this paper
• Free radicals in the physiological control of cell function.

  2002cited by this paper
• Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease

  2002cited by this paper
• Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress.

  2001cited by this paper
• Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease.

  2001cited by this paper
• A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity.

  1999cited by this paper
• SeminarSickle-cell disease

  1997influential reference
• Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst.

  1996cited by this paper
• Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease

  1995cited by this paper
• Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

  1995cited by this paper
• Mortality in sickle cell disease. Life expectancy and risk factors for early death.

  1994cited by this paper
• Mortality in sickle cell disease.

  1994cited by this paper
• Pain in sickle cell disease. Rates and risk factors.

  1991cited by this paper
• Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.

  1990cited by this paper
• 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.

  1982cited by this paper
• THE SIGNIFICANCE OF THE PAUCITY OF SICKLE CELLS IN NEWBORN NEGRO INFANTS

  1948cited by this paper

• A Systematic Review of Medicinal Plants and Their Compounds Validated as Agents for the Management of Sickle Cell Disease

  2024influential citation
• Triterpenoids from the roots of Sanguisorba officinalis and their Nrf2 stimulation activity.

  2023cites this paper
• Protective effect and mechanism of cannabidiol on myocardial injury in exhaustive exercise training mice.

  2022cites this paper
• Apigenin alleviates neomycin-induced oxidative damage via the Nrf2 signaling pathway in cochlear hair cells

  2021cites this paper
• Eritrositlerde Oksidatif Stres Oluşumunda Rol Oynayan Özgül Mekanizmalar ve Koruyucu Antioksidan Sistemler

  2020cites this paper
• Specific Mechanisms and Protective Antioxidant Systems Playing Role in Occurring Oxidative Stress in Erythrocytes

  2020cites this paper
• Genetic Regulation of Redox Balance in β-Thalassemia Trait

  2020cites this paper
• Redox Signaling in Sickle Cell Disease.

  2019cites this paper
• MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell disease.

  2019cites this paper
• Inflammation in sickle cell disease

  2018influential citation
• Triterpenoid Hydroxamates as HIF Prolyl Hydrolase Inhibitors.

  2018cites this paper
• Evaluation of potential antioxidant and anti‐inflammatory effects of Antrodia cinnamomea powder and the underlying molecular mechanisms via Nrf2‐ and NF‐&kgr;B‐dominated pathways in broiler chickens

  2018cites this paper
• Novel antioxidants' synthesis and their anti-oxidative activity through activating Nrf2 signaling pathway.

  2017cites this paper
• Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses

  2016cites this paper
• Oxidative Stress and Sickle Cell Disease

  2016cites this paper
• Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives

  2015cites this paper
• Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: Strategies to treat sickle cell disease

  2015cites this paper
• Oxidative stress in β-thalassaemia and sickle cell disease

  2015cites this paper